Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells.

Ahmed RL, Shaughnessy DP, Knutson TP, Vogel RI, Ahmed K, Kren BT, Trembley JH.

Pharmaceuticals (Basel). 2019 Apr 2;12(2). pii: E50. doi: 10.3390/ph12020050.

2.

Immune characteristics correlating with HSV-1 immune control and effect of squaric acid dibutyl ester on immune characteristics of subjects with frequent herpes labialis episodes.

McTavish H, Zerebiec KW, Zeller JC, Shekels LL, Matson MA, Kren BT.

Immun Inflamm Dis. 2019 Mar;7(1):22-40. doi: 10.1002/iid3.241. Epub 2019 Feb 12.

3.

Evaluation of protein kinase CK2 as a therapeutic target for squamous cell carcinoma of cats.

Cannon CM, Trembley JH, Kren BT, Unger GM, O'Sullivan MG, Cornax I, Modiano JF, Ahmed K.

Am J Vet Res. 2017 Aug;78(8):946-953. doi: 10.2460/ajvr.78.8.946.

PMID:
28738012
4.

Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.

Cannon CM, Trembley JH, Kren BT, Unger GM, O'Sullivan MG, Cornax I, Modiano JF, Ahmed K.

Hum Gene Ther Clin Dev. 2017 Jun;28(2):80-86. doi: 10.1089/humc.2017.008. Epub 2017 Mar 23.

5.

CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer.

Trembley JH, Kren BT, Abedin MJ, Vogel RI, Cannon CM, Unger GM, Ahmed K.

Pharmaceuticals (Basel). 2017 Feb 21;10(1). pii: E25. doi: 10.3390/ph10010025. Review.

6.

CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors.

Ahmed K, Kren BT, Abedin MJ, Vogel RI, Shaughnessy DP, Nacusi L, Korman VL, Li Y, Dehm SM, Zimmerman CL, Niehans GA, Unger GM, Trembley JH.

Oncotarget. 2016 Sep 20;7(38):61789-61805. doi: 10.18632/oncotarget.11442.

7.

Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.

Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH.

Breast Cancer Res. 2015;17:19. doi: 10.1186/s13058-015-0524-0. Epub 2015 Feb 11.

8.

Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice.

Trembley JH, Unger GM, Korman VL, Abedin MJ, Nacusi LP, Vogel RI, Slaton JW, Kren BT, Ahmed K.

PLoS One. 2014 Oct 15;9(10):e109970. doi: 10.1371/journal.pone.0109970. eCollection 2014.

9.

Protein kinase CK2 inhibition induces cell death via early impact on mitochondrial function.

Qaiser F, Trembley JH, Kren BT, Wu JJ, Naveed AK, Ahmed K.

J Cell Biochem. 2014 Dec;115(12):2103-15. doi: 10.1002/jcb.24887.

10.

Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.

Unger GM, Kren BT, Korman VL, Kimbrough TG, Vogel RI, Ondrey FG, Trembley JH, Ahmed K.

Mol Cancer Ther. 2014 Aug;13(8):2018-29. doi: 10.1158/1535-7163.MCT-14-0166. Epub 2014 May 27.

11.

Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.

Trembley JH, Unger GM, Gomez OC, Abedin J, Korman VL, Vogel RI, Niehans G, Kren BT, Ahmed K.

Mol Cell Pharmacol. 2014;6(2):15-25.

12.

Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.

Trembley JH, Unger GM, Korman VL, Tobolt DK, Kazimierczuk Z, Pinna LA, Kren BT, Ahmed K.

Cancer Lett. 2012 Feb 1;315(1):48-58. doi: 10.1016/j.canlet.2011.10.007. Epub 2011 Oct 12.

13.

Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.

Trembley JH, Unger GM, Tobolt DK, Korman VL, Wang G, Ahmad KA, Slaton JW, Kren BT, Ahmed K.

Mol Cell Biochem. 2011 Oct;356(1-2):21-35. doi: 10.1007/s11010-011-0943-x. Epub 2011 Jul 15.

14.

Genomewide microRNA down-regulation as a negative feedback mechanism in the early phases of liver regeneration.

Shu J, Kren BT, Xia Z, Wong PY, Li L, Hanse EA, Min MX, Li B, Albrecht JH, Zeng Y, Subramanian S, Steer CJ.

Hepatology. 2011 Aug;54(2):609-19. doi: 10.1002/hep.24421. Epub 2011 Jun 30.

15.

β-globin matrix attachment region improves stable genomic expression of the Sleeping Beauty transposon.

Sjeklocha L, Chen Y, Daly MC, Steer CJ, Kren BT.

J Cell Biochem. 2011 Sep;112(9):2361-2375. doi: 10.1002/jcb.23159.

16.

Identification of microRNAs during rat liver regeneration after partial hepatectomy and modulation by ursodeoxycholic acid.

Castro RE, Ferreira DM, Zhang X, Borralho PM, Sarver AL, Zeng Y, Steer CJ, Kren BT, Rodrigues CM.

Am J Physiol Gastrointest Liver Physiol. 2010 Oct;299(4):G887-97. doi: 10.1152/ajpgi.00216.2010. Epub 2010 Aug 5.

17.

Emergence of protein kinase CK2 as a key target in cancer therapy.

Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, Van Waes C, Ahmed K.

Biofactors. 2010 May-Jun;36(3):187-95. doi: 10.1002/biof.96. Review.

18.

High-level genomic integration, epigenetic changes, and expression of sleeping beauty transgene.

Zhu J, Park CW, Sjeklocha L, Kren BT, Steer CJ.

Biochemistry. 2010 Feb 23;49(7):1507-21. doi: 10.1021/bi9016846.

19.

MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells.

Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM.

FEBS J. 2009 Nov;276(22):6689-700. doi: 10.1111/j.1742-4658.2009.07383.x. Epub 2009 Oct 16.

20.

Polysome trafficking of transcripts and microRNAs in regenerating liver after partial hepatectomy.

Kren BT, Wong PY, Shiota A, Zhang X, Zeng Y, Steer CJ.

Am J Physiol Gastrointest Liver Physiol. 2009 Dec;297(6):G1181-92. doi: 10.1152/ajpgi.90636.2008. Epub 2009 Sep 24.

Supplemental Content

Loading ...
Support Center